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Abstract: Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and
chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be
a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical
development are traditional inactivated or live attenuated vaccines. Even though these vaccines work
well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles
(VLPs), can offer important advantages in the manufacturing and epitope engineering. We have
previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production
of CVB3-VLPs with enhanced production yield and purity using an improved purification method
consisting of tangential flow filtration and ion exchange chromatography, which is compatible with
industrial scale production. We also resolved the CVB3-VLP structure by Cryo-Electron Microscopy
imaging and single particle reconstruction. The VLP diameter is 30.9 nm on average, and it is
similar to Coxsackievirus A VLPs and the expanded enterovirus cell-entry intermediate (the 135s
particle), which is ~2 nm larger than the mature virion. High neutralizing and total IgG antibody
levels, the latter being a predominantly Th2 type (IgG1) phenotype, were detected in C57BL/6J
mice immunized with non-adjuvanted CVB3-VLP vaccine. The structural and immunogenic data
presented here indicate the potential of this improved methodology to produce highly immunogenic
enterovirus VLP-vaccines in the future.
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1. Introduction
Coxsackievirus B3 (CVB3) is an RNA virus that belongs to the enterovirus genus of Picornaviridae.
Infections caused by the six Coxsackievirus B serotypes (CVB1-6) usually manifest in mild flu-like
symptoms or respiratory illness. However, CVBs can infect several organs after primary infection,
such as the nervous system, pancreas, and heart [1]. Such disseminated infections can lead to
severe organ damage and serious diseases including aseptic meningitis, encephalitis, pancreatitis,
and myocarditis. If myocarditis becomes chronic, it can lead to dilated cardiomyopathy (DCM) which
is a leading cause of heart transplantation. CVB3 is the enterovirus most often responsible for viral
myocarditis [2] and it can also cause hand, foot, and mouth disease (HFMD) outbreaks [3]. CVBs have
also been associated with the development of type 1 diabetes [4–6]. Therefore, CVBs have been
considered as potent targets for the future enterovirus vaccines [6–8].
Besides polio [9] and Enterovirus-71 [10] (EV-A71) vaccines, no clinically approved treatments
or vaccines are available against enteroviruses. To meet the demand for the prevention of CVB
associated diseases, the clinical development of a polyvalent CVB vaccine has recently commenced [6].
CVB vaccines in clinical development and EV-vaccines in clinical use contain either live-attenuated
viruses (oral polio vaccine, OPV) or formalin inactivated viruses (CVB vaccine, inactivated polio
vaccine, EV-A71-vaccine). These vaccines have worked well in the prevention of enterovirus diseases.
However, as a live vaccine, OPV faces safety issues, due to the reversion of the attenuated vaccine
virus strain towards the virulent strain in the vaccine recipients leading to vaccine-associated paralytic
polio and subsequent polio outbreaks [11]. Thus, the use of OPV is becoming difficult, however two of
the three wild poliovirus strains have been declared to be eradicated. Inactivated poliovirus vaccine
has been effective and safe, but this vaccine technology does not allow flexible epitope engineering
and it cannot be used for enterovirus types which do not grow well in cell cultures. With this comes
an increasing demand for new vaccine technologies and cost-effective vaccine production methods
that allow flexible vaccine engineering and the large-scale production of vaccines against different
enterovirus types.
Virus-like particles (VLPs) are empty particles assembled from recombinantly expressed viral
structural proteins, which ensures therefore, that they are non-infectious and can be produced for
viruses which do not grow well in cell cultures. Thus, VLP-based vaccines are not associated with
the safety concerns related to live virus vaccines and offer also important advantages in the vaccine
engineering and manufacturing process. Promising VLP-based vaccine candidates against EVs have
been produced as demonstrated by monovalent VLP-vaccines against CVB3 [12,13], EV-A71 [14],
CVA6 [15], CVA16 [16], and EV-D68 [17] or polyvalent VLP-vaccines against EV-A71, CVA6, CVA10,
and CVA16 [18]. We have previously produced CVB3-VLPs with moderate yields (yield referring to the
total amount of the pure end product protein) [13], while the efficient production of CVB1-VLPs was
described based on a new construct design, use of a baculoviral (flashBAC) genome, and an improved
purification method [19]. In the present study, we aimed to enhance CVB3-VLP production yields and
purity as well as define an industrially scalable production process. Due to these aims, CVB3-VLPs
were produced utilizing a production process similar to that described for CVB1-VLP [19].
Enteroviruses are non-enveloped icosahedral viruses that are around 30 nm in diameter. The capsid
protects an approximately 7.5 kb single-stranded positive-sense RNA genome, which is translated
into a polyprotein that is co-translationally and post-translationally cleaved by the viral proteases 2A
and 3CD to yield structural proteins VP0, VP1, and VP3. These structural proteins assemble into the
viral capsid, wherein the viral RNA is encapsidated. VP0 is further processed into VP2 and VP4 in
a viral RNA-driven autocatalysis reaction yielding the mature virus [20]. The basic building block
(protomer) of the icosahedral capsid contains VP1-VP4 proteins and the entire capsid consists of 60 such
protomers [21]. In mature enteroviruses, VP4 together with the N-terminus of VP1 are located at the
internal surface of the capsid [21]. On the outer surface of the capsid, there are three-fold propeller-like
protrusions, star-shaped five-fold plateaus (called mesa), and depressions (called canyons) surrounding
each plateau [21]. The canyon, often contains the enterovirus receptor-binding site and binding at
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the canyon results in a cascade of structural changes [22], ultimately leading to the release of the
N-terminus of VP1 and VP4 [23] to form the expanded 135S cell-entry intermediate (also called
A-particle) [24]. High-resolution structures of CVB-VLPs have thus far remained unavailable. As such,
here, we aimed to determine the native structure of CVB3-VLPs by cryoEM and image reconstruction.
Structural information provides the possibility to engineer both the stability of the particle and it’s
immunogenic properties. We also compared the VLP structure resolved in this study to the published
CVB3 and CVA16 whole-virus structures to identify possible differences between the mature virus and
the VLP.
Our previously produced CVB3-VLP vaccine induced a robust neutralizing antibody response
in mice, however this result was obtained by utilizing a strong Freund’s adjuvant [13] which is not
allowed for human use. Therefore, we studied the immunogenicity of non-adjuvanted CVB3-VLP
vaccine in mice.
2. Materials and Methods
2.1. Generation of the CVB3-VLP-Encoding Baculoviruses
The baculoviral transfer vector pOET5, containing separate cassettes for the CVB3 VP1-4 capsid
region under the control of the polyhedrin promoter and the 3CD-protease under a CMV promoter
control was ordered from GeneArt (Regensburg, Germany). CMV promoter acts as a weak promoter
in insect cells, decreasing the toxic effects by the 3CD protease [25]. The fully sequenced CVB3 strain
(GenBank accession number M33854.1) was used as a template. The recombinant baculovirus
was produced according to the flashBAC baculovirus expression system manual utilizing the
flashBAC ULTRA baculovirus genome. Baculovirus working stock titer was determined using
BacPAK Baculovirus Rapid Titer Kit (Clontech, Mountain View, CA, USA).
2.2. Production, Purification and Chracterization of CVB3-VLPs
CVB3-VLPs were produced in High-Five insect cells with a multiplicity of infection (MOI) value of
5. The VLP containing production medium was clarified by mixing it with 20 g/L Sartoclear Dynamics
Lab filter aid (diatomaceous earth) and then filtering it through a 0.2 µm filter. CVB3-VLPs were
concentrated from the culture supernatant by tangential flow filtration (TFF), utilizing 750 MWCO
hollow fiber with an ÄKTA Flux system. The buffer was exchanged to 40 mM Tris pH 7.3, 10 mM
MgCl2, 40 mM NaCl, and 0.1% Tween80 with the same system, and the impurities were removed
from the preparation using a HiLoad 26/10 Q Sepharose High Performance anion exchange column
(GE Healthcare). The VLPs were captured into CIMmultus SO3 cation exchange chromatography
column (BIASeparations) and were eluted using NaCl gradient (pure VLP eluted with ~250 mM NaCl).
Purified VLPs were analyzed in mini-PROTEAN TGX stain-free precast gradient gels (4–20%)
(BioRad, Finland). VLP proteins and impurities were assessed by densitometry analysis of SDS-PAGE
gels using the ImageJ software [26]. VP1 and VP3 proteins were detected by Western blotting
using in-house produced rabbit anti-CVB1-6 polyclonal antibody [19] and IRDye-labeled secondary
antibody. Determination of VLP total protein concentration and dynamic light scattering (DLS) analysis
were performed as described [27]. The thermal stability of the VLP particle was characterized by
differential scanning fluorimetry (DSF) as described in [19]. The VLP was also characterized by
transmission electron microscopy (TEM). Formvar coated and carbon evaporated copper grids were
made hydrophilic by UV-C irradiation at 254 nm (2.0 mWatts/cm2) for 10 min. Then, 5 µL of VLP
(0.5 mg/mL) was added on the grid and incubated for 20 s, after which the excess VLP was removed
by blotting with Whatman 3MM paper. The VLPs were negatively stained through the addition of
5 µL 1% Uranyl acetate on the grid for 20 s which was also removed by blotting. The grids were dried
overnight and imaged with a F200 S/TEM (JEOL) transmission electron microscope.
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2.3. Cryo-Electron Microscopy Structural Determination of CVB3-VLP
Data collection was performed using a JEOL JEM 2100F TEM operating at 200 kV. Briefly, a 3.5 µL
of CVB3-VLP containing solution with final concentration of 1.2 µg/mL was placed on Quantifoil
R2/2 Cu 300 mesh grids. After a 1.5-min incubation time, 0.5 µL of NP40 detergent was added for
15 s. The excess solution was removed by automated blotting and quickly plunged into liquid ethane.
The frozen-hydrated CVB3-VLPs were transferred into the EM using a Gatan 626 cryo-transferring
system. The specimen was examined at 80,000 magnification and images were captured using a CCD
camera with a pixel size of 1.6 Ångstroms using SerialEM autofocusing software with defocus range
set to 0.5–2.5 Ångstroms. Digital images with no stigmatism or drift were selected for further analysis.
Cryo-EM micrographs of CVB3-VLP were processed to generate a dataset for single particle
analysis (SPA). Semi-automated particle selection [28] was employed to select a total of 5890 particles
for refinement and reconstruction. Iterative de novo initial models were generated to determine and
cross-validate the particle parameters. To optimize the 2D alignment and orientation determination
during refinement, a polar Fourier transform (PFT) method [29] with radial range pushed to 10
Ångstroms beyond the particle edge was used in conjugation with a center search. The particle
stack was further refined by Euler/center, defocus, scale-factor, and astigmatism screenings using
JSPR. An iterative 3D refinement was carried out using the JSPR package [30]. To determine the
final resolution of the 3D volume, the dataset was divided into two halves (even and odd numbered
particles) [31,32]. Using eotest program from JSPR/EMAN packages [28,30], the final resolution of the
CVB3-VLP was determined to be 10.2 Ångstroms based on the 0.5 Fourier shell correlation cut-off (data
not shown).
2.4. Mouse Immunizations
Male C57BL/6J-mice (7–10 weeks old) were vaccinated by interscapular subcutaneous injections
(i.s.) on days 0, 21, and 35 with 5 µg of non-adjuvanted CVB3-VLP vaccine (n = 5) or with vaccine
buffer (n = 5). Experiments with C57BL/6J mice were conducted at Karolinska Institutet, Stockholm,
Sweden in accordance with the NIH Principles of Laboratory Animal Care and national laws in Sweden
and were approved by the local ethics committee (permission number S 48–14). Blood samples were
collected prior to each immunization, on day 42 and at the experimental end point (day 49) from the
tail vein or by terminal heart puncture (day 49) and used to isolate serum.
2.5. CVB3-VLP Specific ELISA and Neutralization Assay
Two-fold serial dilutions from 1:200 diluted sera of individual mice were analyzed in ELISA for
the presence of CVB3-specific IgG, IgG1 and IgG2a antibodies (Invitrogen, Saint Louis, MO, USA).
Then, 96-well maxisorp plates (Nunc, Fisher Scientific, Vantaa, Finland) were coated with 100 ng of
CVB3-VLPs per well (room temperature, overnight) in PBS. After washing, the plates were blocked
with 0.1% BSA in PBS and the serum samples diluted in PBS containing 2% NaCl, 1% BSA and 0.05%
Tween20 were applied. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma-Aldrich,
Saint Louis, MO, USA), IgG1 or IgG2a (Invitrogen, Saint Louis, MO, USA) and Sigma FAST OPD
substrate (Sigma-Aldrich, Saint Louis, MO, USA) were used for the detection of total IgG or IgG subtype
responses. Absorbance (optical density, OD) was measured at 490 nm in a microplate reader (Victor
1420, Perkin Elmer, Turku, Finland). The background signal (wells without serum) was subtracted
from all OD readings in the plate. A sample was considered positive if the net absorbance value was
above the cut-off value calculated as follows (control mice mean OD + 3 × SD). Serum titres below 200
were considered negative.
CVB3 neutralizing antibodies were measured as previously described [19]. According to previous
studies, uninfected animals that have not been vaccinated occasionally show a neutralizing antibody
titre of 1:4 but not beyond this titre [33].
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3. Results
3.1. Optimized Construct Design, Production Yields and Purity for CVB3-VLP
Previously, we have produced CVB3-VLPs [13] and CVB1-VLPs [19] in insect cells. CVB3-VLPs
have been earlier produced using the Bac-to-Bac baculovirus-insect cell expression system, where the
P1 polyprotein was expressed under polh promoter and 3CD protease was expressed under p10
promoter [13]. Co-expression of CVB3 P1 and 3CD led to P1 polyprotein cleavage into VP0, VP1 and
VP3 by 3CD and subsequent VLP assembly [13]. However, the production yields of the VLPs were
moderate. Subsequently we produced CVB1-VLPs and to enhance the VLP yield, we constructed a
CVB1-VLP construct, in which the P1 polyprotein expression was under the strong polh promoter
and 3CD protease under the weaker CMV promoter [19]. In the new design, the 3CD protease
was produced in low levels, which decreases the toxic effects of 3CD on the host cells and allows
the baculovirus-infected insect cells to produce higher amounts of VLP compared to the previous
design. Also, the baculoviral genome (flashBAC ultra) utilized with the CVB1-VLP production contains
deletions in the non-essential baculoviral protease genes [34], which increases the cell stability and
lowers the burden on the baculovirus-infected cells, allowing for a more efficient production of
the target protein. Another improvement made which enhanced the CVB1-VLPs production yield
involved the selection of the insect cell line. CVB3-VLPs were produced in Spodoptera frugiperda sf9
insect cells [13], whereas CVB1-VLPs were produced in Trichoplusia Ni High Five insect cells [19],
that have been shown to out-perform sf9 cells for VLP production yields [35]. During the current
study, we applied the same construct design, insect cell line and purification method for producing
CVB3-VLPs as that which we have previously used to produce CVB1-VLPs [19].
CVB3-VLPs produced in High Five insect cells were extracted from the cell culture supernatants
with tangential flow filtration and subsequently purified with anion and cation exchange
chromatographic steps. First, the impurities were removed from the concentrated VLP with
anion exchange chromatography. Then, CVB3-VLPs were captured into the SO3 cation exchange
chromatography column and were eluted from the column with a linear NaCl gradient. The VLPs
eluted from the column at a NaCl concentration of ~250 mM into two fractions (Figure 1A). SDS-PAGE
analysis and the subsequent detection of proteins with a stain-free staining method (Figure 1B, left panel)
revealed three prominent proteins of approximately 38 kDa, 31 kDa, and 26 kDa corresponding to
the CVB3 capsid proteins VP0, VP1 and VP3. VP1 and VP3 capsid proteins were also detected with
rabbit anti-CVB1-6 polyclonal antibody in Western Blot analysis (Figure 1B, right panel). According to
TEM-analysis, the particles were intact and had the correct morphology and an average size of 30 nm
(Figure 1C). DLS analysis showed, that the first and the second fraction contained 100% particles with
average hydrodynamic diameters of 27.5 (±0.2) nm and 31.1 (±1.5) nm respectively and the samples
were very monodisperse (polydispersity indexes, PdI: fraction 1: 0.11 ± 0.02, fraction 2: 0.24 ± 0.01)
(Figure 1D). These sizes were comparable with the CVB1-VLPs [19] and CVB3-VLPs [13] we studied
previously. Differential scanning fluorimetry (DSF) was used to analyze the thermal stability of
CVB3-VLP. As we have shown previously for CVB1-VLP, the thermal stability of CVB3-VLP was lower
than that of native viruses and comparable to the thermal stability of CVB1-VLP [19]. Two melting
temperatures (Tm) were determined for CVB3-VLP, Tm1 (34.2 ◦C ± 0.29) that can be assigned to the
initial capsid unfolding and expansion and Tm2 (67.5 ◦C± 0.12) that can be assigned to the denaturation
of the VLPs (Figure 1E).
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averaging technique introduced by Cheng et al. in 1996 [29,31], the icosahedral particles were sorted 
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Figure 1. Purification and characterization of VLP. Final cation exchange chromatography concentration
step and characterization of the purified CVB3-VLPs with SDS-PAGE, Western blotting, TEM, DLS
and DSF. (A) In the final cation exchange chromatography step, the VLP was loaded on the column
in a buffer containing 20 mM Tris pH 7.4, 5 mM MgCl2, 20 mM NaCl and 0.1% Tween80. Captured
VLPs eluted in an approximately 250 mM NaCl concentration using a linear gradient into two fractions
designated 1 and 2 (fraction 1 represented the most concentrated fraction and fraction 2 the more dilute
side fraction; (B) SDS-PAGE and Western blot analyses of purified VLPs. The left panel shows the
stainfree total protein staining of the purified CVB3-VLP fractions 1 and 2. The right panel shows
VP1 and VP3 capsid protein detection by Western blot using an in-house produced rabbit anti-CVB1-6
polyclonal antibody; (C) Transmission Electron Microscopy (TEM) image of the chromatography
purified CVB3-VLP. Scale bar 100 nm, 50,000× magnification. (D) Dynamic light scattering (DLS)
analysis of the purified CVB3-VLP fractions. (E) Thermal stability profile of CVB3-VLP with differential
scanning fluorimetry (DSF). Fluorescence intensity of the dye in the presence of VLPs was plotted
as a function of the temperature, and melting temperatures (Tm) of the VLPs were derived from the
inflection points of the transition curve using the Boltzmann equation [36]. The data is shown as an
average of three independent measurements ± Standard Deviation.
3.2. Structural Analysis of CVB3-VLP
High-resolution structural information is available for several enteroviruses such as CVB3 [21].
However, the structure of CVB-VLPs has remained unavailable. Cryo-EM images of CVB3-VLP
revealed spherical particles of u iform size with on averag , a diameter of ~31 nm (cryo-EM field
vie in Figur 2A and contrast inverted select d particles in Figure 2B). The overall three-dimensional
structure of CVB3-VLPs (res lved here by cryo-EM single particle nalysis) is similar to CVA6-VLP,
EV-A71-VLP, and CVA16 135s particles an i ~2 nm larger than the mature virion of EV-A71 and
CVA16, as well as the CVB3 X-ray st uctur [37–41]. Using a cross-correlative circular averaging
technique introduced by Cheng et al. in 1996 [29,31], the icosahedra particles wer sor ed by a scale
factor based on statistical measures (Figure 2C). To ensure a homogeneous population for single particle
nalysis, particles w th a iameter larger than ~34 nm and smaller th n ~27 nm were ithdrawn
from the analysis; these particles were generally broken and/or collapsed, with irregular shape and
ze. The rem i ing et of mages were furth so t d b sed on Euler orientations (θ, ω, Φ) into
two- ime sional class averages (Figure 2D), from which n ite ative de nova initial model generation
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was carried out. The resolved CVB3-VLP cryo-EM structure has been deposited into worldwide protein
data bank with ID: EMD-22495.
From the cryo-EM density map, the mesa (star-shaped plateau at five-fold axis), the canyon
surrounding the five-fold axis, and propeller-like features at the three-fold axis are clearly resolved
(Figure 2E). Rigid-body fitting of EV-A71 (PDB: 3VBF) revealed that the two adjacent alpha helices
from VP0 do not fit into the density map. A depression at the two-fold icosahedral axis is observed,
which illustrates an open conformation at the junction channel and is similar to CVA6-VLP, EV-A71-VLP,
and CVA16 135s particles. After detecting the above mentioned similarity of CVB3-VLP to CVA16 135s
particles, we further characterized the differences between CVA16 mature virion and the CVB3-VLPs
by carrying out computer simulations for molecular dynamic flexible fitting of atomic structures (using
iMODfit [42] and PDB 5C4W [40]) to calculate the expansion of the CVB3-VLPs. We observed that the
CVB3-VLP diameter is about 30.9 nm on average, in contrast to 28.5 nm of the CVA16 mature virion,
an 8.4 % increase in the overall diameter (Figure 2F–G).
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Figure 2. Structural analysis of CVB3 virus-like particle. (A) Field view of cryo-EM micrographs of
frozen-hydrated CVB3-VLPs. (B) A gallery of selected particles used towards structure determination
(inverted). (C) Particle sorting by scale factor using Polar Fourier Transform method. Particles within
±3% of the average were used to calculate 2D-referece-free class averages shown in (D). (E) 3D surface
rendering 2-fold view of CVB3-VLP colored by radial distance from cold to warm. A depression at
2-fold axis is pointed out. (F,G) Rigid-body fitting and dynamic flexible fitting of CVA6-VLP into
cryo-EM density revealing the expanded size as a result of 2-fold depression.
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3.3. Non-Adjuvanted CVB3-VLPs Induce CVB3-Specific IgG, IgG1-, IgG2a and Neutralizing Antibody
Responses in C57BL/6J Mice
The immunogenicity of the CVB3-VLP vaccine was tested in five C57Bl/6J-mice by immunizing
the animals on three occasions (days 0, 21 and 35) with 5 µg non-adjuvanted vaccine by i.s. injection.
Serum samples were collected on days 0, 21, 35, 42, and 49. Control mice (n = 5) received vaccine
buffer alone. Sera of C57BL/6J-mice immunized with CVB3-VLP vaccines or the vaccine buffer were
analyzed for CVB3-specific serum IgG, IgG1 and IgG2a 49 days after the prime vaccination. All mice
were positive for CVB3-specific IgG by ELISA with geometric mean titer (GMT) 5572 (Figure 3A).
CVB3-specific IgG1 and IgG2a immunoglobulin subtypes which are indicators of Th2 and Th1 type
immune responses were also studied. CVB3-VLP vaccine primarily induced primarily a Th2-type
(IgG1) oriented response with GMT 5572, whereas the Th1-type (IgG2a) GMT was 696 in the sera from
vaccinated animals (Figure 3A).
Sera from CVB3-VLP immunized mice were also analyzed for CVB3 neutralizing ability in vitro
(Figure 3B). All vaccinated mice generated neutralizing antibodies by day 21 (after one vaccination)
with GMT 111. After three vaccinations, the neutralizing GMT increased to 256 (p < 0.01).
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Figure 3. Immunization of mice with VLP. CVB3-VLP vaccines induced CVB3-specific serum IgG, IgG1-,
IgG2a and neutralizing antibody responses in C57BL/6J-mice. (A) IgG, IgG1- and IgG2a ELISA at day
49 post initial vaccination. Antibody titers below 200 were assigned as negative (indicated by horizontal
line); (B) CVB3 neutralizing antibody titers in the sera of mice immunized with CVB3-VLP vaccines in
samples taken at day 0, 21, 35, 42 and 49 (n = 5). Mean IgG-, IgG1-, IgG2a- and neutralizing antibody
titers are indicated by the line ±SEM. The dotted line represents the positive/negative threshold of
neutralizing capacity (dilution 1:16) in the virus neutralization assay. * p < 0.05 and ** p < 0.01 compared
to control mice or day 0 as determined by non-parametric Kruskal-Wallis test.
4. Discussion
CVBs have constantly been among the top 15 enteroviruses most commonly reported to the CDC
by diagno tic laboratories in the US that cause significant morbidity. Currently there are no treatments
or vaccines avail le aga n t CVBs, but the clinical development of a polyvalent formalin-inactivated
whole-virus CVB vaccine is in progress [6,8]. Thus, there is a clear need to develop new vaccine
technologies against CVBs. In addition to the traditional inactivat d vaccin technologies, new VLP
technologies can offer solutions for cost-effective manufacturing and epitope engine ring of future
CVB vaccines. Previously, we have pr duced CVB3-VLP [13] d CVB1-VLP [19] vaccines i insect
cells and purified tho e with ion exchange ch matography. In the present study, our aim was to
e hance th CVB3-VLP yield by utilizing a similar expression c nstruct design and purification method
to that employed for the CVB1-VLP [19]. As with the production of CVB1-VLP, here, we utilize
a baculoviral (flashBAC) genome containing deletions in the non-essential protease genes [34] and
the 3CD protease w s produced in low lev ls by utilizing a CMV promoter. Thes changes educ
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the toxic effects of baculoviral and [34] enteroviral [20] proteases on the production cell line. In the
CVB3-VLP concentration step, the PEG-precipitation method used previously was replaced with
tangential flow filtration and the impurities were removed from the concentrated VLP by anion
exchange chromatography. The final cation exchange chromatographic capture and concentration step
was performed as we have described previously [13,19]. The optimizations in the construct design,
baculoviral genome, and purification method accounted for the enhanced production yield and purity
of CVB3-VLP, and furthermore, this purification method is also a process that is compatible with
industrial scale production. Since the construct design, production cell line and purification method
utilized here differ to those used for the previously produced CVB3-VLP [13], it is impossible to address
how much each change in the production process improved the final yield of the pure CVB3-VLP.
However, we reached our objectives. Firstly, the developed purification method is scalable and utilize
techniques generally used in industrial settings. Secondly, based on the characterization of the pure
CVB3-VLP and the polydispersity Index (PdI) determined by DLS, both pure CVB3-VLP fractions
were very monodisperse, demonstrating that compared to the previously developed purification
method [13], CVB3-VLPs that were more homogenous were successfully purified. Thirdly, the obtained
yield after purification was approximately 1.5 mg/L, which is three times higher than the yield of
CVB3-VLP in our previous study [13].
An atomic-resolution structure of CVB3 virus was resolved by X-ray crystallography
25 years ago [21], however, similar structures of other CVBs are lacking. Also, the structures of
CVB-VLPs have been unresolved until now. In the present study we determined a high-resolution
cryo-EM three-dimensional structure of CVB3-VLP. The capsid surface structures characteristic for
enteroviruses, i.e., mesa (star-shaped plateau at five-fold axis), the canyon surrounding the five-fold
axis, and propeller-like features at the three-fold axis were clearly resolved from the VLP structure.
According to the structure, CVB3-VLPs are ~2 nm larger than the mature virion of CVB3 [21] and
the size difference is also similar to that seen when comparing EV-A71 and CVA16 viruses with their
respective VLPs [37–41]. We found that the CVB3-VLP diameter is about 30.9 nm on average, which is
very similar to the size of CVA6-VLP, EV-A71-VLP, and CVA16 135s particle (the expanded cell-entry
intermediate, also called A-particle) [37,39,41]. The structure of CVB3-VLP axis closely resembles
that of the expanded enterovirus A-particle. The enlargement of the two-fold axis is associated with
mature virion-to-uncoating intermediate states [38]. The fenestration of viral A-particles near the
two-fold axis has been shown for several native enteroviruses including Echovirus 1 and EV-A71 [43,44].
We saw a similar folding in the CVB3-VLP. In the A-particle, VP4 and the RNA-genome are still in
the capsid and the particle is primed for infecting cells. Once the VP4 protein and the genome have
been expulsed, the resulting empty capsid is referred to as empty particle (80S) [43]. Heating of the
native enterovirus capsid results in the formation of both A- and empty-particles [43]. However,
in physiological conditions enterovirus particles resemble the A-particles [44,45]. Since the structure of
CVB3-VLP resembles that of A-particle, the VLP may closely resemble the form of mature virion in
physiological conditions. Poliovirus capsid structure have been stabilized by heat selected mutants [46]
and such mutations have been applied to generate poliovirus VLPs with better immunogenicity [47].
The importance of the solved CVB3-VLP structure is speeding up rational engineering of the CVB
particle to be more stable by introducing point mutations and thus improving its immunogenicity
similarly to poliovirus VLPs.
Most licensed VLP-vaccines contain adjuvants in their vaccine formulas [48] and to the best of our
knowledge, most immunogenicity studies with EV-VLPs have also included adjuvants [12–18,49–51].
Adjuvants improve the quality, magnitude, and duration of the immune response, and generally,
it is thought that vaccines composed of VLPs alone may not sufficiently trigger the innate immunity
response to the level required for optimal stimulation of the adaptive immune system [48]. However,
since we observed that nonadjuvanted CVB1-VLP produced a clear neutralizing immune reaction in
our previous study [19], we wanted to explore the immunogenicity of CVB3-VLPs in C57BL/6J mice
without the use of adjuvants. We hypothesized that VLPs should be able to induce robust immune
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responses, since the VLP structures present a repetitive arrangement of antigens [52], making them
immunogenic without the need for immunomodulatory substances. CVB infections induce rapid and
strong neutralizing antibody responses in mice [33,53] and humans [54] and the protective efficacy of
vaccines correlates well with the magnitude of the antibody response [8,13,27,33,55]. In our previous
studies with inactivated CVB1 whole-virus vaccines [55] and with CVB1-VLP vaccine [19] high total
IgG and neutralizing antibody responses were induced in C57BL/6J male mice with non-adjuvanted
vaccines and the responses were primarily Th2-type (IgG1) oriented. Here, the immune response of
CVB3-VLP was like the previously measured immune response of inactivated whole-virus vaccines [55]
and CVB1-VLP vaccine [19] in C57BL/6J male mice demonstrating the immunogenic potential of
non-adjuvanted CVB3-VLP. In our previous study with CVB3-VLP, the immunogenicity of the VLP
was studied in BALB/c mice in the presence of Freund’s adjuvant [13]. The total IgG and neutralizing
antibody responses in the previous study [13] were slightly higher than the antibody responses obtained
here without adjuvant, but it is important to note that the previous and the current experiment represent
independent studies and the results obtained from different mice strains should not be compared
quantitatively to each other. The structural and immunogenic data presented here indicate the potential
of this improved methodology to produce highly immunogenic VLP-vaccines in the future.
Author Contributions: Conceptualization, O.H.L., V.P.H., R.H.C., M.F.-T., V.M., H.H.; M.M.H., M.A.B. and V.M.S.;
methodology, M.M.H., M.A.B., V.M.S., A.S.-K., N.V.V.S., O.H.L., V.P.H., R.H.C., M.F.-T., V.M., and H.H.; validation,
M.M.H., M.A.B., V.M.S., and A.S.-K.; formal analysis, M.M.H., M.A.B., V.M.S., L.X., O.V., S.S., A.S.-K., N.V.V.S.,
T.O., and B.A.; resources, V.P.H., R.H.C., M.F.-T., V.M., and H.H.; data curation, M.M.H., V.P.H., M.A.B., R.H.C.,
V.M.S., and M.F.-T.; writing—original draft preparation, M.M.H.; writing—review and editing, M.M.H., M.A.B.,
V.M.S., L.X., O.V., S.S., A.S.-K., N.V.V.S., T.O., B.A., H.H., V.M., M.F.-T., V.P.H., and O.H.L.; visualization, M.M.H.
and M.A.B.; supervision, M.M.H., M.A.B., V.M.S., A.S.-K., H.H., R.H.C., M.F.-T., V.P.H., and O.H.L.; funding
acquisition, O.H.L., V.P.H., R.H.C., M.F.-T., V.M., H.H., and M.M.H. All authors have read and agreed to the
published version of the manuscript.
Funding: This research was funded by The Academy of Finland, grant number 309455 (M.M.H.); Business
Finland [Project THERDIAB 1843/31/2014]; FiDiPro grant NOVAC Dnro 1913/31/2012]; The Strategic Research
Program in Diabetes at Karolinska Institutet (M.F.-T.); the Swedish Child Diabetes Foundation (V.S. and M.F.-T.),
the Swedish Medical Research Council (M.F-T., 2017-02020); Business Finland (FiDiPro grant 1913/31/2012)
(R.H.C.), the Academy of Finland (grant 266492) (R.H.C.), the National Institute of Food and Agriculture and the
National Institutes of Health (grants: AI095382, EB021230, CA198880) (R.H.C.). Vactech Ltd., ArcDia Ltd., JILAB
Ltd. and Finnmedi Research Ltd. are acknowledged for their contribution within THERDIAB. We acknowledge
Biocenter Finland for the infrastructure support.
Acknowledgments: We would like to thank the laboratory personnel of the Protein Dynamics and the Virology
groups at the Faculty of Medicine and Life Technologies at Tampere University and the members of the PKL
animal facility at Karolinska University Hospital Huddinge (Stockholm, Sweden). This work made use of Tampere
Microscopy Center facilities at Tampere University. We would like to specially thank Mari Honkanen for teaching
the use of the transmission electron microscopy and for all the help during the imaging.
Conflicts of Interest: H.H. owns stocks and is the chairman of the board of Vactech Ltd., which develops vaccines
against picornaviruses. H.H. and M.F.-T. serve on the scientific advisory board of Provention Bio Inc., which is
developing an enterovirus vaccine. The other authors have no conflict of interest to declare.
References
1. Sin, J.; Mangale, V.; Thienphrapa, W.; Gottlieb, R.A.; Feuer, R. Recent progress in understanding coxsackievirus
replication, dissemination, and pathogenesis. Virology 2015, 484, 288–304. [CrossRef]
2. Peischard, S.; Ho, H.T.; Theiss, C.; Strutz-Seebohm, N.; Seebohm, G. A kidnapping story: How Coxsackievirus
B3 and its host cell interact. Cell. Physiol. Biochem. 2019, 53, 121–140. [CrossRef]
3. Han, Z.; Zhang, Y.; Huang, K.; Wang, J.; Tian, H.; Song, Y.; Yang, Q.; Yan, D.; Zhu, S.; Yao, M.; et al.
Two COXSACKIEVIRUS B3 outbreaks associated with hand, foot, and mouth disease in China and the
evolutionary history worldwide. BMC Infect. Dis. 2019, 19, 466. [CrossRef] [PubMed]
4. Laitinen, O.H.; Honkanen, H.; Pakkanen, O.; Oikarinen, S.; Hankaniemi, M.M.; Huhtala, H.; Ruokoranta, T.;
Lecouturier, V.; Andre, P.; Harju, R.; et al. Coxsackievirus B1 is associated with induction of beta-cell
autoimmunity that portends type 1 diabetes. Diabetes 2014, 63, 446–455. [CrossRef] [PubMed]
Microorganisms 2020, 8, 1287 11 of 13
5. Sioofy-Khojine, A.; Lehtonen, J.; Nurminen, N.; Laitinen, O.H.; Oikarinen, S.; Huhtala, H.; Pakkanen, O.;
Ruokoranta, T.; Hankaniemi, M.M.; Toppari, J.; et al. Coxsackievirus B1 infections are associated with the
initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 2018, 61, 1193–1202.
[CrossRef] [PubMed]
6. Hyöty, H.; Leon, F.; Knip, M. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B.
Expert Rev. Vaccines 2018, 17, 1071–1083. [CrossRef] [PubMed]
7. Dunne, J.L.; Richardson, S.J.; Atkinson, M.A.; Craig, M.E.; Dahl-Jørgensen, K.; Flodström-Tullberg, M.;
Hyöty, H.; Insel, R.A.; Lernmark, Å.; Lloyd, R.E.; et al. Rationale for enteroviral vaccination and antiviral
therapies in human type 1 diabetes. Diabetologia 2019, 62, 744–753. [CrossRef] [PubMed]
8. Stone, V.M.; Hankaniemi, M.M.; Laitinen, O.H.; Sioofy-Khojine, A.B.; Lin, A.; Lozano, I.M.D.; Mazur, M.A.;
Marjomäki, V.; Loré, K.; Hyöty, H.; et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and
has a strong protective capacity in mice and nonhuman primates. Sci. Adv. 2020, 6, eaaz2433. [CrossRef]
9. Lien, G.; Heymann, D.L. The problems with polio: Toward eradication. Infect. Dis. Ther. 2013, 2, 167–174.
[CrossRef]
10. Chang, P.-C.; Chen, S.-C.; Chen, K.-T. The current status of the disease caused by enterovirus 71 infections:
Epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int. J. Environ. Res. Public
Health 2016, 13, 890. [CrossRef]
11. Lukashev, A.N. Recombination among picornaviruses. Rev. Med. Virol. 2010, 20, 327–337. [CrossRef]
[PubMed]
12. Zhang, L.; Parham, N.; Zhang, F.; Aasa-Chapman, M.M.I.; Gould, E.; Zhang, H. Vaccination with
coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Vaccine 2012, 30, 2301–2308. [CrossRef] [PubMed]
13. Koho, T.; Koivunen, M.R.; Oikarinen, S.; Kummola, L.; Mäkinen, S.; Mähönen, A.J.; Sioofy-Khojine, A.-B.;
Marjomäki, V.S.; Kazmertsuk, A.; Junttila, I.S.; et al. Coxsackievirus B3 VLPs purified by ion exchange
chromatography elicit strong immune responses in mice. Antivir. Res. 2014, 104, 93–101. [CrossRef]
[PubMed]
14. Salmons, B.; Lim, P.-Y.; Djurup, R.; Cardosa, J. Non-clinical safety assessment of repeated intramuscular
administration of an EV-A71 VLP vaccine in rabbits. Vaccine 2018, 36, 6623–6630. [CrossRef] [PubMed]
15. Shen, C.; Ku, Z.; Zhou, Y.; Li, D.; Wang, L.; Lan, K.; Liu, Q.; Huang, Z. Virus-like particle-based vaccine
against coxsackievirus A6 protects mice against lethal infections. Vaccine 2016, 34, 4025–4031. [CrossRef]
[PubMed]
16. Liu, Q.; Yan, K.; Feng, Y.; Huang, X.; Ku, Z.; Cai, Y.; Liu, F.; Shi, J.; Huang, Z. A virus-like particle vaccine for
coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine
2012, 30, 6642–6648. [CrossRef] [PubMed]
17. Dai, W.; Zhang, C.; Zhang, X.; Xiong, P.; Liu, Q.; Gong, S.; Geng, L.; Zhou, D.; Huang, Z. A virus-like
particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine 2018, 36, 653–659.
[CrossRef]
18. Zhang, W.; Dai, W.; Zhang, C.; Zhou, Y.; Xiong, P.; Wang, S.; Ye, X.; Liu, Q.; Zhou, D.; Huang, Z. A virus-like
particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective
immunity. Emerg. Microbes Infect. 2018, 7. [CrossRef]
19. Hankaniemi, M.M.; Stone, V.M.; Andrejeff, T.; Heinimäki, S.; Sioofy-Khojine, A.-B.; Marjomäki, V.; Hyöty, H.;
Blazevic, V.; Flodström-Tullberg, M.; Hytönen, V.P.; et al. Formalin treatment increases the stability and
immunogenicity of coxsackievirus B1 VLP vaccine. Antivir. Res. 2019, 171, 104595. [CrossRef]
20. Laitinen, O.H.; Svedin, E.; Kapell, S.; Nurminen, A.; Hytönen, V.P.; Flodström-Tullberg, M. Enteroviral
proteases: Structure, host interactions and pathogenicity. Rev. Med. Virol. 2016, 26, 251–267. [CrossRef]
21. Muckelbauer, J.K.; Kremer, M.; Minor, I.; Diana, G.; Dutko, F.J.; Groarke, J.; Pevear, D.C.; Rossmann, M.G.
The structure of coxsackievirus B3 at 3.5 å resolution. Structure 1995, 3, 653–667. [CrossRef]
22. Lyu, K.; Ding, J.; Han, J.-F.; Zhang, Y.; Wu, X.-Y.; He, Y.-L.; Qin, C.-F.; Chen, R. Human enterovirus 71
uncoating captured at atomic resolution. J. Virol. 2013, 88, 3114–3126. [CrossRef] [PubMed]
23. Fricks, C.E.; Hogle, J.M. Cell-induced conformational change in poliovirus: Externalization of the amino
terminus of VP1 is responsible for liposome binding. J. Virol. 1990, 64, 1934–1945. [CrossRef] [PubMed]
24. De Sena, J.; Mandel, B. Studies on the in vitro uncoating of poliovirus. Virology 1976, 70, 470–483. [CrossRef]
Microorganisms 2020, 8, 1287 12 of 13
25. Lin, S.-Y.; Yeh, C.-T.; Li, W.-H.; Yu, C.-P.; Lin, W.-C.; Yang, J.-Y.; Wu, H.-L.; Hu, Y.-C. Enhanced enterovirus 71
virus-like particle yield from a new baculovirus design. Biotechnol. Bioeng. 2015, 112, 2005–2015. [CrossRef]
26. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.;
Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012,
9, 676–682. [CrossRef]
27. Hankaniemi, M.M.; Laitinen, O.H.; Stone, V.M.; Sioofy-Khojine, A.-B.; Määttä, J.; Larsson, P.G.;
Marjomäki, V.S.; Hyöty, H.; Flodström-Tullberg, M.; Hytönen, V.P. Optimized production and purification
of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine 2017, 35, 3718–3725.
[CrossRef]
28. Tang, G.; Peng, L.; Baldwin, P.R.; Mann, D.S.; Jiang, W.; Rees, I.; Ludtke, S.J. EMAN2: An extensible image
processing suite for electron microscopy. J. Struct. Biol. 2007, 157, 38–46. [CrossRef]
29. Baker, T.S.; Cheng, R. A model-based approach for determining orientations of biological macromolecules
imaged by cryoelectron microscopy. J. Struct. Biol. 1996, 116, 120–130. [CrossRef]
30. Guo, F.; Jiang, W. Single particle cryo-electron microscopy and 3-D reconstruction of viruses. Breast Cancer
2014, 1117, 401–443. [CrossRef]
31. Cheng, R.H.; Olson, N.H.; Baker, T.S. Cauliflower mosaic virus: A 420 subunit (T = 7), multilayer structure.
Virology 1992, 186, 655–668. [CrossRef]
32. Henderson, R.; Sali, A.; Baker, M.L.; Carragher, B.; Devkota, B.; Downing, K.H.; Egelman, E.H.; Feng, Z.;
Frank, J.; Grigorieff, N.; et al. Outcome of the first electron microscopy validation task force meeting. Structure
2012, 20, 205–214. [CrossRef] [PubMed]
33. Stone, V.M.; Hankaniemi, M.M.; Svedin, E.; Sioofy-Khojine, A.-B.; Oikarinen, S.; Hyöty, H.; Laitinen, O.H.;
Hytönen, V.P.; Flodström-Tullberg, M. A Coxsackievirus B vaccine protects against virus-induced diabetes in
an experimental mouse model of type 1 diabetes. Diabetologia 2017, 61, 476–481. [CrossRef] [PubMed]
34. Hitchman, R.B.; Possee, R.D.; Crombie, A.T.; Chambers, A.; Ho, K.; Siaterli, E.; Lissina, O.; Sternard, H.;
Novy, R.; Loomis, K.; et al. Genetic modification of a baculovirus vector for increased expression in insect
cells. Cell Biol. Toxicol. 2009, 26, 57–68. [CrossRef]
35. Krammer, F.; Schinko, T.; Palmberger, D.; Tauer, C.; Messner, P.; Grabherr, R. Trichoplusia ni cells (High Five)
are highly efficient for the production of influenza a virus-like particles: A comparison of two insect cell
lines as production platforms for influenza vaccines. Mol. Biotechnol. 2010, 45, 226–234. [CrossRef]
36. Niesen, F.H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions
that promote protein stability. Nat. Protoc. 2007, 2, 2212–2221. [CrossRef]
37. Chen, J.; Zhang, C.; Zhou, Y.; Zhang, X.; Shen, C.; Ye, X.; Jiang, W.; Huang, Z.; Cong, Y. A 3.0-angstrom
resolution cryo-electron microscopy structure and antigenic sites of coxsackievirus A6-like particles. J. Virol.
2018, 92, e01257-17. [CrossRef]
38. Shingler, K.L.; Yoder, J.L.; Carnegie, M.S.; Ashley, R.E.; Makhov, A.M.; Conway, J.F.; Hafenstein, S.
The enterovirus 71 A-particle forms a gateway to allow genome release: A cryoEM study of picornavirus
uncoating. PLoS Pathog. 2013, 9, e1003240. [CrossRef]
39. Wang, X.; Peng, W.; Ren, J.; Hu, Z.; Xu, J.; Lou, Z.; Li, X.; Yin, W.; Shen, X.; Porta, C.; et al. A sensor-adaptor
mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012, 19, 424–429.
[CrossRef]
40. Ren, J.; Wang, X.; Zhu, L.; Hu, Z.; Gao, Q.; Yang, P.; Li, X.; Wang, J.; Shen, X.; Fry, E.; et al. Structures of
Coxsackievirus A16 capsids with native antigenicity: Implications for particle expansion, receptor binding,
and immunogenicity. J. Virol. 2015, 89, 10500–10511. [CrossRef]
41. Ren, J.; Wang, X.; Hu, Z.; Gao, Q.; Sun, Y.; Li, X.; Porta, C.; Walter, T.S.; Gilbert, R.J.C.; Zhao, Y.; et al.
Picornavirus uncoating intermediate captured in atomic detail. Nat. Commun. 2013, 4, 1929. [CrossRef]
[PubMed]
42. López-Blanco, J.R.; Chacón, P. iMODFIT: Efficient and robust flexible fitting based on vibrational analysis in
internal coordinates. J. Struct. Biol. 2013, 184, 261–270. [CrossRef] [PubMed]
43. Wang, X.; Ku, Z.; Zhang, X.; Ye, X.; Chen, J.; Liu, Q.; Zhang, W.; Zhang, C.; Fu, Z.; Jin, X.; et al. Structure,
immunogenicity, and protective mechanism of an engineered enterovirus 71-like particle vaccine mimicking
80S empty capsid. J. Virol. 2017, 92, e01330-17. [CrossRef] [PubMed]
Microorganisms 2020, 8, 1287 13 of 13
44. Ruokolainen, V.; Domanska, A.; Laajala, M.; Pelliccia, M.; Butcher, S.J.; Marjomäki, V. Extracellular albumin
and endosomal ions prime enterovirus particles for uncoating that can be prevented by fatty acid saturation.
J. Virol. 2019, 93. [CrossRef]
45. Ward, T.; Powell, R.M.; Chaudhry, Y.; Meredith, J.; Almond, J.W.; Kraus, W.; Nelsen-Salz, B.; Eggers, H.J.;
Evans, D.J. Fatty acid-depleted albumin induces the formation of echovirus a particles. J. Virol. 2000, 74,
3410–3412. [CrossRef]
46. Adeyemi, O.O.; Nicol, C.; Stonehouse, N.; Rowlands, D.J. Increasing type 1 poliovirus capsid stability by
thermal selection. J. Virol. 2016, 91, e01586-16. [CrossRef]
47. Fox, H.; Knowlson, S.; Minor, P.D.; Macadam, A. Genetically Thermo-Stabilised, Immunogenic Poliovirus
Empty Capsids; a Strategy for Non-replicating Vaccines. PLoS Pathog. 2017, 13, e1006117. [CrossRef]
48. Cimica, V.; Galarza, J.M. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin. Immunol.
2017, 183, 99–108. [CrossRef]
49. Zhang, C.; Zhang, X.; Zhang, W.; Dai, W.; Xie, J.; Ye, L.; Wang, H.; Chen, H.; Liu, Q.; Gong, S.; et al. Enterovirus
D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and
confer protection against lethal viral infection in mice. Emerg. Microbes Infect. 2018, 7. [CrossRef]
50. Wang, C.; Zheng, X.; Gai, W.; Wong, G.; Wang, H.; Jin, H.; Feng, N.; Zhao, Y.; Zhang, W.; Li, N.; et al.
Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific
humoral and cellular immune response in mice. Antivir. Res. 2017, 140, 55–61. [CrossRef]
51. Ku, Z.; Liu, Q.; Ye, X.; Cai, Y.; Wang, X.; Shi, J.; Li, D.; Jin, X.; An, W.; Huang, Z. A virus-like particle based
bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Vaccine 2014, 32, 4296–4303. [CrossRef] [PubMed]
52. Braun, M.; Jandus, C.; Maurer, P.; Hammann-Haenni, A.; Schwarz, K.; Bachmann, M.F.; Speiser, D.E.;
Romero, P. Virus-like particles induce robust human T-helper cell responses. Eur. J. Immunol. 2011, 42,
330–340. [CrossRef] [PubMed]
53. Svedin, E.; Utorova, R.; Hühn, M.H.; Larsson, P.G.; Stone, V.M.; Garimella, M.G.; Lind, K.; Hägglöf, T.;
Pincikova, T.; Laitinen, O.H.; et al. A link between a common mutation in cftr and impaired innate and
adaptive viral defense. J. Infect. Dis. 2017, 216, 1308–1317. [CrossRef] [PubMed]
54. Torfason, E.G.; Reimer, C.B.; Keyserling, H.L. Subclass restriction of human enterovirus antibodies.
J. Clin. Microbiol. 1987, 25, 1376–1379. [CrossRef]
55. Hankaniemi, M.M.; Stone, V.M.; Sioofy-Khojine, A.-B.; Heinimäki, S.; Marjomäki, V.; Hyöty, H.; Blazevic, V.;
Laitinen, O.H.; Flodström-Tullberg, M.; Hytönen, V.P. A comparative study of the effect of UV and formalin
inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine 2019, 37, 5962–5971.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
